Heat Biologics

172 articles about Heat Biologics

• Heat Biologics Completes Name Change to NightHawk Biosciences; Trading to Commence Under “NHWK” Effective at the Market Open Today

  5/3/2022

  Heat Biologics, Inc. today announced that it has completed its name change from Heat Biologics, Inc. to NightHawk Biosciences, Inc.

• Heat Biologics (NightHawk Biosciences) Announces that its Elusys Therapeutics Subsidiary has Executed a Contract to Deliver ANTHIM® to the Canadian Government

  4/27/2022

  Heat Biologics, Inc. announced to shareholders that its Elusys Therapeutics subsidiary has finalized a contract with the Canadian government to deliver ANTHIM®, a treatment for inhalation anthrax, for use against a potential anthrax attack.

• Heat Biologics (“NightHawk Biosciences”) Completes Acquisition of Elusys Therapeutics

  4/20/2022

  Heat Biologics, Inc. today announced it has completed the acquisition of Elusys Therapeutics, Inc.

• Heat Biologics Announces Planned Name Change to NightHawk Biosciences, Reflecting Company’s Evolution, Therapeutic Pipeline Expansion, Vertical Integration and New Biodefense Capabilities

  4/19/2022

  Heat Biologics, Inc. announced that it is changing the name of the Company to NightHawk Biosciences, Inc., effective May 3, 2022, to better reflect the Company’s evolution, including expansion of its therapeutic pipeline, the vertical integration of capabilities from drug discovery to manufacturing and commercialization, as well as the Company’s new biodefense capabilities.

• Heat Biologics’ Scorpion Subsidiary Announces Planned Development of New Kansas Commercial/Biodefense Biomanufacturing Facility

  4/18/2022

  Heat Biologics, Inc. announced a planned development partnership of its Scorpion Biological Services subsidiary with a private developer, the State of Kansas and local and university affiliates, to support the development of a new biodefense-focused large molecule and biologics biomanufacturing facility in Manhattan, Kansas.

• 

  Heat Biologics' New Biodefense Facility to Create 500 Kansas Jobs

  4/18/2022

  Heat Biologics announced a new development underway in its partnership with Scorpion Biological Services to develop a manufacturing facility in Manhattan, Kansas.

• Heat Biologics’ Announces Planned Investor and Media Livestream Event to Discuss Latest Developments

  4/14/2022

  Heat Biologics, Inc. announced it plans to host an investor and media livestream event on Tuesday, April 19, 2022 at 10:30 AM Eastern Time to discuss the latest developments.

• Heat Biologics Unveils Enhanced Allogeneic Cell Manufacturing Process

  3/25/2022

  Heat Biologics,Inc., a clinical-stage biopharmaceutical company focused on developing novel biodefense assets and first-in-class therapies to modulate the immune system, unveiled enhanced allogeneic cell therapy manufacturing capabilities through its Scorpion Biological Services subsidiary.

• Heat Biologics Announces Appointment of Greg Burel, Former Director of the Strategic National Stockpile, to its Biothreat Advisory Board and as Senior Advisor to the Company

  3/23/2022

  Heat Biologics, Inc. announces the appointment of Greg Burel, former Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response Director of the Strategic National Stockpile, to the Company’s Biothreat Advisory Board and as a senior advisor to the Company.

• Heat Biologics Provides Year-End 2021 Business Update

  3/14/2022

  Heat Biologics, Inc., a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, provided strategic, financial, and operational updates for the year ended December 31, 2021.

• Heat Biologics Announces Planned Transfer to the NYSE American

  2/2/2022

  Heat Biologics, Inc., a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, announced that it plans to change its listing from the Nasdaq Capital Market to the NYSE American stock exchange.

• Heat Biologics Announces New PTX-35 Preclinical Data in Organ Transplantation and Provides Update on HS-110

  1/12/2022

  Heat Biologics, Inc. today announced promising new preclinical data regarding PTX-35 has been accepted for publication in the American Journal of Transplantation.

• Heat Biologics Announces Planned Acquisition of Elusys Therapeutics

  12/21/2021

  Heat Biologics, Inc. today announced it has executed a definitive merger agreement to acquire Elusys Therapeutics, a commercial-stage biodefense company and the manufacturer of ANTHIM® (obiltoxaximab) Injection, pursuant to which Elusys will merge into a wholly owned subsidiary of Heat.

• Heat Biologics Unveils RapidVax®, A Novel Cellular Vaccine Platform Targeting Known and Unknown Emerging Biological Threats

  11/30/2021

  Heat Biologics, Inc. today unveiled its new RapidVax® cellular vaccine platform at the 2021 World Antiviral Congress.

• Heat Biologics Provides Third Quarter 2021 Business Update

  11/10/2021

  Heat Biologics,Inc. (“Heat”)(NASDAQ:HTBX), today provided strategic, financial, and operational updates for the third quarter ended September 30, 2021.

• 

  BioSpace Movers & Shakers, Oct. 8

  10/8/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Heat Biologics Appoints Paul Tebbey as Senior Vice President of Product Development and Portfolio Strategy

  10/6/2021

  Heat Biologics, Inc. today announced the appointment of Paul Tebbey, Ph.D. as Senior Vice President of Product Development and Portfolio Strategy.

• Heat Biologics CEO to Present at the Cantor Fitzgerald Global Healthcare Conference on September 29th

  9/15/2021

  Heat Biologics, Inc. today announced that Jeff Wolf, Chief Executive Officer of Heat Biologics, will be presenting at the Cantor Fitzgerald Global Healthcare Conference being held virtually between September 27-30, 2021.

• Heat Biologics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

  9/9/2021

  Heat Biologics, Inc. today announced that Jeff Wolf, Chief Executive Officer of Heat Biologics, will be presenting at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually between September 13-15, 2021.

• Heat Biologics to Provide Corporate UpdateConference call scheduled for September 2nd at 11:00 AM ET

  8/30/2021

  Heat Biologics, Inc. today announced CEO Jeff Wolf will host a conference call on Thursday, September 2 nd at 11:00 A.M. Eastern Time to provide an update on the Company’s activities.